For research use only. Not for therapeutic Use.
Avanafil (Cat. No: A000366) is a highly selective oral phosphodiesterase 5 inhibitor. Phase I, II and III clinical trials showed that compared with another phosphodiesterase 5 inhibitors, avanafil has the characteristics of rapid onset, short duration of action, less adverse reactions, and good clinical efficacy and safety in the treatment of erectile dysfunction.
| CAS Number | 330784-47-9 |
| Synonyms | 330784-47-9; STENDRA; Spedra; (S)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790 |
| Molecular Formula | C23H26ClN7O3 |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | >17.6mg/mL in DMSO |
| Storage | -20°C |
| InChI | 1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1 |
| InChIKey | WEAJZXNPAWBCOA-INIZCTEOSA-N |
| SMILES | COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl |
